Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash & Current Investments (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Cash & Current Investments readings, the most recent being $467.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments rose 13.36% year-over-year to $467.7 million, compared with a TTM value of $467.7 million through Dec 2025, up 13.36%, and an annual FY2025 reading of $467.7 million, up 13.36% over the prior year.
  • Cash & Current Investments hit $467.7 million in Q4 2025 for Apellis Pharmaceuticals, down from $480.6 million in the prior quarter.
  • The five-year high for Cash & Current Investments was $852.8 million in Q2 2022, with the low at $267.0 million in Q1 2021.
  • Median Cash & Current Investments over the past 5 years was $441.9 million (2021), compared with a mean of $489.4 million.
  • The sharpest move saw Cash & Current Investments crashed 67.3% in 2021, then skyrocketed 213.11% in 2022.
  • Year by year, Cash & Current Investments stood at $700.6 million in 2021, then decreased by 21.05% to $553.1 million in 2022, then crashed by 36.3% to $352.3 million in 2023, then increased by 17.12% to $412.6 million in 2024, then rose by 13.36% to $467.7 million in 2025.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $467.7 million, $480.6 million, and $371.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.